11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The integrated stress response (ISR) is a central cellular adaptive program that is activated by diverse stressors including ER stress, hypoxia and nutrient deprivation to orchestrate responses via activating transcription factor 4 (ATF4). We hypothesized that ATF4 is essential for the adaptation of human glioblastoma (GB) cells to the conditions of the tumor microenvironment and is contributing to therapy resistance against chemotherapy. ATF4 induction in GB cells was modulated pharmacologically and genetically and investigated in the context of temozolomide treatment as well as glucose and oxygen deprivation. The relevance of the ISR was analyzed by cell death and metabolic measurements under conditions to approximate aspects of the GB microenvironment. ATF4 protein levels were induced by temozolomide treatment. In line, ATF4 gene suppressed GB cells (ATF4sh) displayed increased cell death and decreased survival after temozolomide treatment. Similar results were observed after treatment with the ISR inhibitor ISRIB. ATF4sh and ISRIB treated GB cells were sensitized to hypoxia-induced cell death. Our experimental study provides evidence for an important role of ATF4 for the adaptation of human GB cells to conditions of the tumor microenvironment characterized by low oxygen and nutrient availability and for the development of temozolomide resistance. Inhibiting the ISR in GB cells could therefore be a promising therapeutic approach.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

          Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematologic toxic effects in 7 percent of patients. The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity. Copyright 2005 Massachusetts Medical Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The integrated stress response.

            In response to diverse stress stimuli, eukaryotic cells activate a common adaptive pathway, termed the integrated stress response (ISR), to restore cellular homeostasis. The core event in this pathway is the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) by one of four members of the eIF2α kinase family, which leads to a decrease in global protein synthesis and the induction of selected genes, including the transcription factor ATF4, that together promote cellular recovery. The gene expression program activated by the ISR optimizes the cellular response to stress and is dependent on the cellular context, as well as on the nature and intensity of the stress stimuli. Although the ISR is primarily a pro-survival, homeostatic program, exposure to severe stress can drive signaling toward cell death. Here, we review current understanding of the ISR signaling and how it regulates cell fate under diverse types of stress.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

              Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor.
                Bookmark

                Author and article information

                Contributors
                M.Ronellenfitsch@gmx.net
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                8 July 2021
                8 July 2021
                2021
                : 11
                : 14161
                Affiliations
                [1 ]GRID grid.411088.4, ISNI 0000 0004 0578 8220, Dr. Senckenberg Institute of Neurooncology, , University Hospital Frankfurt, Goethe University, ; Schleusenweg 2-16, 60528 Frankfurt am Main, Germany
                [2 ]GRID grid.7497.d, ISNI 0000 0004 0492 0584, German Cancer Consortium (DKTK), ; Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany
                [3 ]GRID grid.7839.5, ISNI 0000 0004 1936 9721, Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, , Goethe University, ; Frankfurt am Main, Germany
                [4 ]GRID grid.411088.4, ISNI 0000 0004 0578 8220, University Cancer Center Frankfurt (UCT), , University Hospital Frankfurt, Goethe University, ; Frankfurt am Main, Germany
                [5 ]GRID grid.7839.5, ISNI 0000 0004 1936 9721, Institute of Biochemistry II, , Goethe University, ; Frankfurt am Main, Germany
                [6 ]GRID grid.511808.5, Cardio-Pulmonary Institute, ; Frankfurt am Main, Germany
                Article
                93663
                10.1038/s41598-021-93663-1
                8266821
                34239013
                84821576-a9be-4a36-b0ee-147a2286256e
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 February 2021
                : 18 June 2021
                Funding
                Funded by: Frankfurt Research Funding, Medical Faculty, Goethe University
                Funded by: Else Kröner-Forschungskolleg (EKF)
                Funded by: German Research Foundation (DFG)
                Award ID: MU 4216/1-1
                Award Recipient :
                Funded by: State of Hessen, LOEWE program
                Funded by: Senckenberg Foundation
                Funded by: University Cancer Center Frankfurt (UCT)
                Funded by: Johann Wolfgang Goethe-Universität, Frankfurt am Main (1022)
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                cancer,cell biology
                Uncategorized
                cancer, cell biology

                Comments

                Comment on this article